285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors by Marcus Butler, David Hong, Ryan Sullivan, Matthew Frigault, Sarah Boross-Harmer, Ecaterina Dumbrava, Jean-Marc Navenot, Svetlana Fayngerts, Jane Bai, Elliot Norry, Paula Fracasso, Russell Pachynski, Partow Kebriaei, Amy Sauer, Francine Brophy

Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient by Scott C. Lien, Dalam Ly, S. Y. Cindy Yang, Ben X. Wang, Derek L. Clouthier, Michael St. Paul, Ramy Gadalla, Babak Noamani, Carlos R. Garcia-Batres, Sarah Boross-Harmer, Philippe L. Bedard, Trevor J. Pugh, Anna Spreafico, Naoto Hirano, Albiruni R. A. Razak, Pamela S. Ohashi

Get full text

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors by Neda Stjepanovic, Amit M Oza, Anna Spreafico, Stephanie Lheureux, Marcus O Butler, Pamela S Ohashi, Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Dave Cescon, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Lillian L Siu, Daniel D De Carvalho

Get full text

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors by David S. Hong, Marcus O. Butler, Russell K. Pachynski, Ryan Sullivan, Partow Kebriaei, Sarah Boross-Harmer, Armin Ghobadi, Matthew J. Frigault, Ecaterina E. Dumbrava, Amy Sauer, Francine Brophy, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry G. Batrakou, Ruoxi Wang, Luisa M. Solis, Dzifa Yawa Duose, Joseph P. Sanderson, Andrew B. Gerry, Diane Marks, Jane Bai, Elliot Norry, Paula M. Fracasso

Get full text